Study protocol for a multicentre randomised controlled trial evaluating the efficacy of an online yoga intervention in high-grade glioma patients and their caregivers: the YINOTA-O-trial.
Study Goal
The researchers aimed to investigate the effects of mindfulness-based online yoga on emotional distress, quality of life, and stress-associated physiological parameters in high-grade glioma patients and their caregivers compared to a waiting control group.
Results Summary
The study hypothesizes better outcomes in the intervention group compared to the waiting control group, including reduced anxiety, fear of progression, depression, and improved quality of life, along with favorable changes in biochemical stress parameters. Results are pending as the study is ongoing.
Population
Adult high-grade glioma (WHO grades 3 and 4) patients and their caregivers.
Effective Dosage
1 hour per week of mindfulness-based online yoga.
Duration
8 weeks.
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
mindfulness-based online yoga | neutral | emotional distress | high-grade glioma patients and their caregivers | - | investigate the effects | #1 |
mindfulness-based online yoga | neutral | quality of life | high-grade glioma patients and their caregivers | - | investigate the effects | #2 |
mindfulness-based online yoga | neutral | stress-associated physiological parameters | high-grade glioma patients and their caregivers | - | investigate the effects | #3 |
mindfulness-based online yoga | decrease | generalised anxiety | intervention group | - | hypothesise better outcomes | #4 |
mindfulness-based online yoga | decrease | fear of progression | intervention group | - | hypothesise better outcomes | #5 |
mindfulness-based online yoga | decrease | depression | intervention group | - | hypothesise better outcomes | #6 |
mindfulness-based online yoga | increase | quality of life | intervention group | - | hypothesise better outcomes | #7 |
mindfulness-based online yoga | neutral | brain-derived neurotrophic factor (BDNF) | intervention group | - | hypothesise better outcomes | #8 |
mindfulness-based online yoga | neutral | dehydroepiandrosterone (DHEA)/dehydroepiandrosterone sulfate (DHEAS) | intervention group | - | hypothesise better outcomes | #9 |
mindfulness-based online yoga | neutral | ferritin | intervention group | - | hypothesise better outcomes | #10 |
mindfulness-based online yoga | decrease | hair cortisol | intervention group | - | hypothesise better outcomes | #11 |
mindfulness-based online yoga | decrease | Generalised Anxiety Disorder scale-7 | patients | - | significant effect detections | #12 |
mindfulness-based online yoga | decrease | Generalised Anxiety Disorder scale-7 | caregivers | - | significant effect detections | #13 |
INTRODUCTION: High-grade glioma patients and their caregivers often suffer from distress and a lower quality of life. Results from studies with patients with mixed cancer entities suggest that yoga can be an effective support. However, it is unclear whether this also applies to high-grade glioma patients and their caregivers. This study aims to investigate the effects of mindfulness-based online yoga for patients and their caregivers on emotional distress, quality of life and stress-associated physiological parameters compared with a waiting control group (WCG). METHODS & ANALYSIS: The study is designed as a multicentre randomised controlled trial. Adult glioma patients (central nervous system WHO grades 3 and 4) and their caregivers will be recruited. Examined yoga instructors deliver the intervention (1 hour per week) in a synchronous format over 8 weeks via video conferencing. The WCG will receive standard care during the 8-week waiting period. Data will be collected before and after the end of the intervention and another 3 months later using questionnaires as well as blood serum and hair samples to evaluate biochemical stress parameters. Primary outcome is self-reported generalised anxiety and secondary outcomes are self-reported fear of progression, depression and quality of life as well as brain-derived neurotrophic factor (BDNF), dehydroepiandrosterone (DHEA)/dehydroepiandrosterone sulfate (DHEAS), ferritin and hair cortisol. We hypothesise better outcomes in the intervention group compared with the WCG at all measurement points. 70 patients and 70 caregivers will be recruited consecutively. Primary endpoints are significant effect detections in the Generalised Anxiety Disorder scale-7 of patients and caregivers at the end of the intervention. Analyses of covariance will be performed to analyse the treatment effects. ETHICS AND DISSEMINATION: The Ethics Committee of the University of Würzburg approved the YINOTA-O ( TRIAL REGISTRATION NUMBER: German Clinical Trials Register No. DRKS00029554.